Question 1

What is Gilead Sciences's P/E ratio?

Accepted Answer

Gilead Sciences (GILD) P/E ratio is 17.7× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Gilead Sciences?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Gilead Sciences specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Gilead Sciences's P/E ratio high or low?

Accepted Answer

Gilead Sciences's P/E ratio of 17.7× is below its own 5-year average of 81.6× and below the sector median of 24.2×. That places the current reading at the 37th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Gilead Sciences's historical P/E ratio range?

Accepted Answer

In the available daily series, Gilead Sciences (GILD) P/E ratio has ranged from a low of 6.8× in 2016 to a high of 1114.6× in 2025. The 5-year average is 81.6× and the 5-year median is 18.7×.

Question 7

What was Gilead Sciences's P/E ratio in 2025?

Accepted Answer

Gilead Sciences (GILD) P/E ratio at the end of 2025 was 17.9×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Gilead Sciences's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$152B	$8.51B	17.9×	-222.2×	Dec 31, 2025
2024	$115B	$480M	240.2×	+222.3×	Dec 31, 2024
2023	$101B	$5.66B	17.8×	-5.6×	Dec 31, 2023
2022	$107B	$4.59B	23.4×	+8.8×	Dec 31, 2022
2021	$91.2B	$6.23B	14.7×	-579.8×	Dec 31, 2021
2020	$73.1B	$123M	594.4×	+579.2×	Dec 31, 2020
2019	$82.3B	$5.39B	15.3×	+0.5×	Dec 31, 2019
2018	$80.7B	$5.46B	14.8×	-5.4×	Dec 31, 2018
2017	$93.6B	$4.63B	20.2×	+13.3×	Dec 31, 2017
2016	$94.2B	$13.5B	7.0×	-1.0×	Dec 31, 2016
2015	$145B	$18.1B	8.0×	-3.7×	Dec 31, 2015
2014	$142B	$12.1B	11.7×	-25.7×	Dec 31, 2014
2013	$115B	$3.07B	37.5×	+16.0×	Dec 31, 2013
2012	$55.7B	$2.59B	21.5×	+10.7×	Dec 31, 2012
2011	$30.2B	$2.8B	10.8×	+0.7×	Dec 31, 2011
2010	$29.3B	$2.9B	10.1×	-4.7×	Dec 31, 2010
2009	$38.9B	$2.64B	14.8×	-8.6×	Dec 31, 2009
2008	$46.6B	$2B	23.4×	-3.0×	Dec 31, 2008
2007	$42.6B	$1.62B	26.4×	—	Dec 31, 2007
2006	$29.7B	-$1.19B	—	—	Dec 31, 2006
2005	$24B	$814M	29.5×	-4.1×	Dec 31, 2005
2004	$15.1B	$449M	33.6×	—	Dec 31, 2004
2003	$11.8B	-$72M	—	—	Dec 31, 2003
2002	$6.67B	$72.1M	92.5×	—	Dec 31, 2002


Agilent Technologies (A)	23.1×
Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Gilead Sciences (GILD) 2002-2026

P/E Ratio daily chart for Gilead Sciences (GILD)

Historical P/E Ratio for Gilead Sciences (GILD) from 2002 to 2025

About P/E Ratio at Gilead Sciences (GILD)

Gilead Sciences P/E Ratio by Year

Gilead Sciences P/E Ratio 2025: 17.9×

Gilead Sciences P/E Ratio 2024: 240.2×

Gilead Sciences P/E Ratio 2023: 17.8×

Gilead Sciences P/E Ratio 2022: 23.4×

Gilead Sciences P/E Ratio 2021: 14.7×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Gilead Sciences (GILD) Key Financials